Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by Analysts

Agenus Inc. (NASDAQ:AGEN - Get Free Report) has earned an average recommendation of "Hold" from the six brokerages that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $8.75.

Several research firms recently issued reports on AGEN. Robert W. Baird cut their target price on Agenus from $6.00 to $3.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 12th. StockNews.com upgraded Agenus from a "sell" rating to a "hold" rating in a research report on Friday, March 21st. HC Wainwright reiterated a "neutral" rating on shares of Agenus in a report on Tuesday, March 18th. Finally, B. Riley reiterated a "buy" rating on shares of Agenus in a research report on Monday.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Corton Capital Inc. purchased a new stake in Agenus in the fourth quarter worth about $36,000. Virtu Financial LLC purchased a new position in shares of Agenus in the 4th quarter worth about $51,000. Apollon Wealth Management LLC purchased a new stake in Agenus during the 4th quarter valued at about $55,000. HighTower Advisors LLC raised its holdings in Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock worth $122,000 after buying an additional 7,530 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of Agenus during the fourth quarter valued at approximately $69,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Stock Up 3.5 %

Shares of AGEN traded up $0.10 during trading hours on Friday, hitting $2.97. The company had a trading volume of 1,252,641 shares, compared to its average volume of 607,551. Agenus has a 52-week low of $1.38 and a 52-week high of $19.69. The stock's 50 day moving average price is $2.18 and its 200 day moving average price is $3.07. The firm has a market cap of $75.17 million, a P/E ratio of -0.26 and a beta of 1.58.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, beating analysts' consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. On average, research analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.